- Kincell Bio has signed a multi-year contract with a leading biotechnology company for the production of early-phase clinical material of an allogeneic cell therapy product.
- The agreement follows Kincell Bio’s acquisition of a GMP-ready facility in April 2024 and will enhance its manufacturing capabilities.
Kincell Bio has announced a new multi-year partnership with a leading biotechnology company for the production of early-phase clinical material of an allogeneic cell therapy product.
The contract follows Kincell Bio’s acquisition of a GMP-ready facility in April 2024. This facility, which is now operational, will support the production of the cell therapy product and expand the company’s manufacturing capabilities.
“Kincell Bio continues to build meaningful partnerships with our customers, providing critical CMC development and manufacturing expertise to support their clinical trials,” said Bruce Thompson, CEO of Kincell Bio. He added, “Our entire team is energized to support innovative approaches that help bring new cellular therapies to market and help patients.”
Overview of outsourcing trends 
